Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer
Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer
复制标题
DOI：
10.1159/000091184
复制
发表时间：
2006-01-01
期刊：
影响因子：
3.5
通讯作者：
Fakih, M
中科院分区：
文献类型：
--
作者：
Ailawadhi, S;Sunga, A;Fakih, M
目的：探讨转移性结直肠癌（MCRC）患者癌胚抗原（CEA）峰的发生率及其对临床结局的影响。研究方法：对2000年1月至2004年5月在Roswell Park癌症研究所接受化疗的MCRC患者进行了回顾性图表审查。CEA激增定义为从基线增加> 20%，随后一个或多个随后的CEA水平与基线相比下降> 20%。研究CEA峰的发生率及其与临床结局的关系。结果：89例患者可评价CEA激增。10例患者记录了CEA激增。所有10名患者的CEA激增持续< 4个月，并与临床获益相关。CEA激增与原发肿瘤部位、转移性疾病部位或肿瘤分化程度之间无显著相关性。结论：在接受MCRC化疗的患者中可以观察到CEA激增，并且通常与临床获益相关。没有一个CEA激增符合美国临床肿瘤学会对CEA进展的定义。开始化疗后CEA升高，除非持续> 4个月，否则不能用作疾病进展的指标。版权所有（C）2006 S. Karger AG，巴塞尔。
Objectives: To investigate the incidence of carcinoembryonic antigen (CEA) surge in patients with metastatic colorectal cancer (MCRC) and its implications on clinical outcome. Methods: A retrospective chart review of patients with MCRC treated with chemotherapy at Roswell Park Cancer Institute from January 2000 to May 2004 was conducted. A CEA surge was defined as an increase of > 20% from baseline followed by a > 20% drop in one or more subsequent CEA levels compared to baseline. The incidence of CEA surge and its association with clinical outcome was investigated. Results: Eighty-nine patients were evaluable for CEA surge. A CEA surge was documented in 10 patients. The CEA surge lasted < 4 months in all 10 patients and was associated with a clinical benefit. No significant correlation was noted between CEA surge and site of primary tumor, site of metastatic disease, or tumor differentiation. Conclusions: CEA surges can be observed in patients receiving chemotherapy for MCRC and are often associated with a clinical benefit. None of the CEA surges satisfied the American Society of Clinical Oncology definition of CEA progression. A rise in CEA after initiation of chemotherapy, unless lasting > 4 months, cannot be used as an indicator of progressive disease. Copyright (C) 2006 S. Karger AG, Basel.